SLU-PP-332 is a research compound often discussed next to peptides, but it is not a peptide. It is a synthetic small molecule that activates estrogen-related receptors (ERRs).
CoreVials SLU-PP-332 is for laboratory research only, not for human or animal use.
What are ERRs?
ERRs are nuclear receptors. Nuclear receptors sit in cells and help control which genes turn on. ERR family members (ERRalpha, ERRbeta, ERRgamma) help regulate energy and mitochondrial gene programs.
SLU-PP-332 is described in the literature as a pan-ERR agonist, meaning it can activate more than one ERR subtype.
Why do people call it an exercise mimetic?
In mouse studies from the Burris / Billon research line, SLU-PP-332 turned on gene programs that look similar to an acute aerobic exercise signature in muscle. Treated mice also showed endurance and metabolic changes in controlled experiments.
"Exercise mimetic" is a research nickname. It does not mean the compound replaces training in people. There are no published human clinical trials establishing that claim.
What did the mouse metabolic papers report?
Follow-on work examined obesity and metabolic syndrome models. Reports describe increased fatty acid oxidation, lower fat mass accumulation, and improved insulin-sensitivity markers in those mouse systems.
Those results are preclinical. Mouse dose levels and delivery routes do not translate into a human protocol by simple arithmetic.
How is this different from GLP-1 research tools?
Compounds such as tirzepatide and retatrutide act on gut-hormone receptor pathways. SLU-PP-332 acts on ERR nuclear receptors and exercise-linked gene programs.
Different locks. Different research questions. See also MOTS-c research overview for another metabolism lane.
Beginner checklist
- SLU-PP-332 is a small molecule, not an amino-acid peptide chain.
- Most public evidence is mouse pharmacology and metabolism work.
- Human outcome data are not established in registered trials as of the current literature used for this overview.
- Research-use materials are not consumer supplements.
References
- Billon, C., et al. (2023). Synthetic ERR agonist work describing exercise-linked gene programs and endurance phenotypes in mice. ACS Chemical Biology / related Burris lab publications.
- Billon, C., et al. (2024). A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics. Read the study
- PubMed record: PMID 37739806
